Jude Samul­ski's gene ther­a­py com­pa­ny just raised $235M for clin­i­cal de­vel­op­ment

A gene ther­a­py com­pa­ny that’s played a key role in back­ing treat­ments now owned by No­var­tis and Pfiz­er is step­ping up this morn­ing with a mon­ster ven­ture raise aimed at mak­ing it a lead­ing clin­i­cal de­vel­op­er in one of the hottest fields in biotech.

Askle­pios Bio­phar­ma­ceu­ti­cal, which prefers to be less for­mal­ly known as AskBio, sold a mi­nor­i­ty stake in the com­pa­ny to TPG and Vi­da Ven­tures for $225 mil­lion. And the com­pa­ny’s founders and board mem­bers are putting in an­oth­er $10 mil­lion — skin in the game.

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.